Security key
05153U107
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 943,845
- Total 13F value
- $6,696,633
- Share change
- -84,390
- SEC-reported price per share
- $7.10
- Number of holders
- 20
- Value change
- -$600,474
- Number of buys
- 10
- Number of sells
- 6
- Shares outstanding
- 104,146,273
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
20
Top holders
10
AURA full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Aura Biosciences, Inc. SEC filings
Aura Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 05153U107
Recent filing periods:
Ownership snapshot
Top reported holders of AURA - Aura Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TCG Crossover GP II, LLC
Disclosed value leader
TCG Crossover GP II, LLC
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
13D/G row: TCG Crossover GP II, LLC
Showing 1-6 of 15 holder rows.
Quick read
TCG Crossover GP II, LLC leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TCG Crossover GP II, LLC's linked filing trail.
Comparable ownership
Top 5
TCG Crossover GP II, LLC
9.9%
SUVRETTA CAPITAL MANAGEMENT, LLC
7.6%
Long Focus Capital Management, LLC
6.6%
Frazier Life Sciences Public Fund...
6.3%
BlackRock, Inc.
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TCG Crossover GP II, LLC |
13D/G
Chen Yu
|
9.9%
|
$64,540,664
9,533,333 shares
|
$0 | 05 May 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
7.6%
|
$30,091,360
4,701,775 shares
|
+$10,524,518 | 30 Jun 2025 |
| Long Focus Capital Management, LLC |
13F
13D/G
Company
|
6.6%
from 13D/G
|
$30,905,004
4,619,582 shares
|
— | 31 Mar 2026 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
6.3%
|
$20,523,185
4,032,060 shares
|
+$4,675,216 | 31 Dec 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
4.4%
|
$32,536,212
4,582,436 shares
|
+$8,849,753 | 30 Jun 2026 |
| Advent Life Sciences LLP |
13D/G
Rajesh Parekh, Ph.D.
|
3.3%
|
$11,768,148
2,071,857 shares
|
$0 | 13 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
20
Shares
943,845
Rows available
20
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q4 2025 Across Filers
Q4 2025 holders
116
Q2 2026 holders
20
Holder diff
-96
| Investor | Q4 2025 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend